Taking into account the same effect of sorafenib and IL-27 on anti-tumor and antiangiogenesis, we reasoned that the combination of IL-27 and sorafenib might cooperate synergistically to treat bladder cancer. Here, IL27 is linked to urinary bladder carcinoma.